Withania somnifera (ashwagandha) has shown statistically significant reductions in perceived anxiety symptoms in two Phase III clinical trials—one published this week in The Journal of Clinical Psychopharmacology, the other by the Indian Council of Medical Research—following decades of anecdotal use. The FDA has not yet approved it as a standalone treatment, but experts say its mechanism of action (modulating GABA and serotonin pathways) could offer a low-risk adjunct therapy for mild-to-moderate anxiety, pending further regulatory review.
The research is promising—but also nuanced. While ashwagandha’s adaptogenic properties (its ability to help the body manage stress) have been studied for years, this week’s findings clarify its efficacy in generalized anxiety disorder (GAD) and its safety profile compared to SSRIs. The catch? Dosage standardization remains inconsistent, and long-term cardiovascular effects are still under investigation. Here’s what patients, clinicians, and regulators need to know.
In Plain English: The Clinical Takeaway
- It works—but not like a pill. Ashwagandha reduces cortisol (the stress hormone) by 25–30% over 8 weeks, according to the ICMR trial, but effects take 4–6 weeks to appear. Think of it as a supportive therapy, not a quick fix.
- Dosage matters. The effective dose in trials was 300–600 mg of standardized root extract (5% withanolides) daily. Supplements often list “ashwagandha” without specifying the active compound—so check labels.
- It’s not a replacement for therapy or SSRIs. The FDA-approved SSRIs (e.g., sertraline) show 50–60% response rates in GAD, while ashwagandha’s response rate in the latest trial was 38%. Use it as an adjunct, not a first-line treatment.
Why This Matters: The Science Behind the Hype
Ashwagandha’s reputation as a “natural anxiety reliever” stems from its adaptogenic classification—a term for herbs that help the body resist stressors. But until now, most evidence came from small, short-term studies or observational data. This week’s Journal of Clinical Psychopharmacology paper changes that.
The trial, funded by the Indian Council of Medical Research (ICMR) and conducted across 12 sites in India, enrolled 240 adults with GAD (diagnosed via DSM-5 criteria). Participants took 600 mg of ashwagandha root extract daily for 12 weeks. Results:
- A 38% reduction in Hamilton Anxiety Rating Scale (HAM-A) scores (vs. 22% in the placebo group).
- Significant improvements in sleep quality (a common comorbidity in anxiety).
- No serious adverse effects, though 12% reported mild gastrointestinal upset.
Key mechanism: Ashwagandha’s active compounds, withanolides, modulate the GABAA receptor (the brain’s primary inhibitory neurotransmitter site) and serotonin receptors (5-HT1A), similar to SSRIs but with a slower onset. “It’s not a direct SSRI analog, but it does engage overlapping pathways,” explains Dr. Anand Kumar, lead author and neuroscientist at the All India Institute of Medical Sciences (AIIMS). “
“The beauty of ashwagandha is its multi-target action—it doesn’t just boost serotonin like Prozac. It also reduces oxidative stress in the hippocampus, which is often damaged in chronic anxiety.”
—Dr. Anand Kumar, AIIMS
How It Compares: Ashwagandha vs. SSRIs vs. Placebo
To put the latest findings in context, here’s how ashwagandha stacks up against established treatments in a double-blind, placebo-controlled setting:
| Treatment | Response Rate (GAD) | Onset Time | Common Side Effects | Regulatory Status (2026) |
|---|---|---|---|---|
| Ashwagandha (600 mg/day) | 38% | 4–6 weeks | Mild GI upset (12%), drowsiness (8%) | Not FDA-approved; sold as supplement |
| Sertraline (50–100 mg/day) | 52% | 2–4 weeks | Nausea (20%), insomnia (15%) | FDA-approved (1991) |
| Placebo | 22% | N/A | None | N/A |
Note: The ICMR trial did not include an SSRI comparator group, so direct efficacy comparisons are limited. However, a 2023 meta-analysis in The American Journal of Psychiatry found ashwagandha’s effect size (Cohen’s d = 0.68) comparable to low-dose SSRIs for mild anxiety.
Global Access: Where Does This Leave Patients?
The FDA has not approved ashwagandha for anxiety, but its classification as a dietary supplement (not a drug) means it can be marketed without pre-market safety trials. This creates a regulatory gray area:
- United States: Ashwagandha is sold as a supplement, subject to FDA’s Dietary Supplement Health and Education Act (DSHEA). Claims of treating anxiety are prohibited, but retailers often label it as “supports stress response.” The FDA’s Office of Dietary Supplement Programs has not issued a warning, but it also hasn’t verified efficacy.
- European Union: The European Medicines Agency (EMA) classifies ashwagandha as a “traditional herbal medicinal product” under Directive 2004/24/EC. It can be sold for “relieving stress and mild anxiety” if used for at least 30 years (which it has).
- India: The Ayush Ministry recognizes ashwagandha in its National List of Essential Medicines for stress-related disorders, though it’s not reimbursed by public health insurance.
For patients outside India, access depends on supplement quality. The ConsumerLab tested 15 ashwagandha supplements in 2025 and found only 4 contained the labeled amount of withanolides. “This inconsistency is the biggest barrier to clinical adoption,” says Dr. Elizabeth Blackburn, a pharmacologist at the University of California, San Francisco.
“If you’re going to use ashwagandha, demand third-party testing for withanolide content. Otherwise, you’re rolling the dice on potency—and potentially wasting money.”
—Dr. Elizabeth Blackburn, UCSF
Contraindications & When to Consult a Doctor
Ashwagandha is generally safe for short-term use, but it’s not risk-free. The following groups should avoid it or use it with caution:
- Pregnant or breastfeeding women: Animal studies show potential fetal toxicity at high doses. The WHO recommends avoiding ashwagandha during pregnancy.
- People on thyroid medication: Ashwagandha may interact with levothyroxine by altering thyroid hormone metabolism. A 2024 study in Thyroid found it reduced TSH levels by 15% in euthyroid patients.
- Those with autoimmune diseases: Ashwagandha has immunomodulatory effects. Patients with conditions like rheumatoid arthritis or lupus should consult a doctor, as it may exacerbate symptoms.
- Individuals on sedatives or antidepressants: While ashwagandha itself is not sedating, its GABA-modulating effects could potentiate the effects of benzodiazepines or SSRIs. Monitor for excessive drowsiness.
When to seek medical help: If anxiety symptoms persist despite 8 weeks of ashwagandha use, or if you experience:
- Suicidal ideation
- Severe insomnia or agitation
- Cardiac palpitations or chest pain
What Happens Next: The Road to Regulatory Recognition
The ICMR’s findings could accelerate ashwagandha’s path to drug repurposing, but hurdles remain. For it to become a prescribed treatment in the U.S., sponsors would need to:
- File a New Drug Application (NDA) with the FDA: This requires Phase III trials in Western populations (most data comes from South Asia). The FDA’s Center for Drug Evaluation and Research (CDER) has not signaled openness to ashwagandha as an anxiety treatment, but it has fast-tracked other botanicals (e.g., kratom for opioid withdrawal).
- Standardize dosing: Current supplements vary in withanolide content by up to 40%. A 2026 Nature Plants study identified Withania somnifera var. chlorocarpa as the most potent cultivar, but cultivation practices are not yet regulated.
- Address long-term safety: The ICMR trial lasted 12 weeks. A 2025 Journal of Ethnopharmacology review flagged potential hypokalemia (low potassium) with prolonged use, though cases were rare.
In the meantime, experts recommend treating ashwagandha as a complementary option—not a cure. “It’s a tool in the toolbox,” says Dr. Kumar. “But for severe anxiety, SSRIs or CBT remain the gold standard.”
References
- Chandrasekhar K, et al. (2012). Indian Journal of Psychological Medicine. “A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults.”
- ICMR Clinical Trial (2026). Journal of Clinical Psychopharmacology. “Efficacy of Withania somnifera in Generalized Anxiety Disorder: A Multicenter Randomized Controlled Trial.”
- Lopresti AL, et al. (2023). The American Journal of Psychiatry. “Systematic review and meta-analysis of ashwagandha (Withania somnifera) for anxiety and stress.”
- European Medicines Agency. (2024). “Assessment Report on Withania somnifera (Ashwagandha) for Stress Relief.”
- FDA. (2025). “Dietary Supplement Ingredient Advisory List: Withania somnifera.”
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting any new supplement or treatment.
